Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. (Q43143715)

14 November 2017

Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. (English)

1 reference

14 November 2017

0 references

0 references

1 reference

4

1 reference

14 November 2017

8

1 reference

14 November 2017

13

1 reference

14 November 2017

14

1 reference

14 November 2017

Larisa I Labzin

3

0 references

David A Hume

David A Hume

10

0 references

Maria A Halili

Maria A Halili

1

0 references

Katharine M Irvine

Katharine M Irvine

11

0 references

Erica Lovelace

7

Erica Lovelace

1 reference

14 November 2017

Melanie R Andrews

2

1 reference

14 November 2017

Gabriele Matthias

5

1 reference

14 November 2017

Chun Cao

6

1 reference

14 November 2017

Giang T Le

9

1 reference

14 November 2017

Patrick Matthias

12

1 reference

14 November 2017

language of work or name

1 reference

3 March 2010

1 reference

Journal of Leukocyte Biology

14 November 2017

1 reference

14 November 2017

87

1 reference

14 November 2017

6

1 reference

14 November 2017

1103-1114

1 reference

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

14 November 2017

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Identification of novel isoform-selective inhibitors within class I histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Highly Potent and Selective Histone Deacetylase 6 Inhibitors Designed Based on a Small-Molecular Substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Histone deacetylase inhibitors in inflammatory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Trichostatin A attenuates airway inflammation in mouse asthma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Histone acetylation and deacetylation: importance in inflammatory lung diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Differential effects of CpG DNA on IFN-beta induction and STAT1 activation in murine macrophages versus dendritic cells: alternatively activated STAT1 negatively regulates TLR signaling in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

PU.1 and ICSBP control constitutive and IFN-gamma-regulated Tlr9 gene expression in mouse macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Erythroid Kruppel-like factor regulates the G1 cyclin dependent kinase inhibitor p18INK4c

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Plasminogen activator inhibitor-1 in vascular thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Cutting edge: Essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Regulation of microglial inflammatory response by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

The essential role of Oct-2 in LPS-induced expression of iNOS in RAW 264.7 macrophages and its regulation by trichostatin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

ATF-2 regulates lipopolysaccharide-induced transcription in macrophage cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Inhibition of iNOS expression and NO production by anti-inflammatory steroids. Reversal by histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Loss of PU.1 expression following inhibition of histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

Histone H4 HDAC activity is necessary for expression of the PU.1 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0509363

21 January 2018

Identifiers

DOI

10.1189/JLB.0509363

1 reference

14 November 2017

1 reference